Skip to main
NVCR

Novocure (NVCR) Stock Forecast & Price Target

Novocure (NVCR) Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 17%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

NovoCure Ltd has demonstrated positive financial momentum, reporting a 4% increase in 4Q25 revenue to $174.4 million and an 8% increase for full-year 2025 revenue to $655.4 million compared to the previous year. The company experienced notable growth in prescriptions for its Optune Lua device for non-small cell lung cancer (NSCLC) and reported strong domestic net sales of Optune Gio, contributing to a positive outlook for continued revenue growth in the U.S. and internationally, particularly with new national reimbursement in Spain expected to enhance revenue further in 2026.

Bears say

NovoCure Ltd has experienced a decline in revenue projections, with estimates for 2026 total revenue reduced to $711.3 million from a prior expectation of $738.9 million, driven by challenges in the launch of its NSCLC programs. Moreover, significant risks persist, including potential safety signals from ongoing clinical programs, competition from alternative treatments, and regulatory hurdles that could negatively influence revenue generation. Overall, the company's outlook is hindered by the possibility of lower than anticipated adoption rates for products like Optune, coupled with the downtrend in sales and adoption for its TTFields technology across multiple indications.

Novocure (NVCR) has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 17% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Novocure and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Novocure (NVCR) Forecast

Analysts have given Novocure (NVCR) a Buy based on their latest research and market trends.

According to 6 analysts, Novocure (NVCR) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $28.08, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $28.08, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Novocure (NVCR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.